Full text is available at the source.
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
Drugs targeting GLP-1 and GIP receptors for heart protection, type 2 diabetes, and obesity: how they work and clinical findings
AI simplified
Abstract
Tirzepatide, a first-in-class GLP-1/GIP receptor co-agonist, has shown significant reductions in glycemia and body weight in phase 3 trials for type 2 diabetes.
- Tirzepatide is currently approved for managing type 2 diabetes and is awaiting approval for obesity management.
- It has demonstrated superior efficacy in reducing glycemia and body weight compared to GLP-1 receptor mono-agonism with semaglutide.
- Significant body weight reductions were observed in individuals with obesity, even in those without diabetes.
- Tirzepatide enhances lipid metabolism, reduces blood pressure, and lowers liver fat content.
- Pooled phase 2/3 data indicate cardiovascular safety in type 2 diabetes patients.
- A post hoc analysis suggests that tirzepatide may slow the decline of kidney function in individuals with type 2 diabetes.
AI simplified